SAP and Boehringer Ingelheim Create Smart App Prototype to Track Counterfeit Pharmaceuticals


WALLDORFSAP SE (NYSE: SAP) is announcing a smart app designed to track, trace and authenticate prescription medicines in the United States. Developed in partnership with leading global pharmaceutical research company Boehringer Ingelheim, the smart app will enable law enforcement officials to potentially detect illicit, counterfeit or unapproved Boehringer Ingelheim medicines being smuggled into the United States or sold illegally.

The smart app will allow U.S. law enforcement officials across the country to scan the 2D barcode on Boehringer Ingelheim-manufactured life-enhancing medications and authenticate them before the medicines reach patients.

“The law enforcement smart app utilizes SAP’s scalable and secure blockchain solution for manufacturers to drastically improve the pharmaceutical supply chain from start to finish,” said SAP’s global GM for Consumer Industries, Matt Laukaitis. “As this app demonstrates, vertical industry expertise is a critical success factor in delivering innovations to protect patients and ensure access to authentic, life-enhancing medicines.”

Passed into law in 2013, the U.S. Drug Supply Chain Security Act (DSCSA) aimed to boost the FDA’s ability to protect U.S. patients by developing a connected, digital system to trace prescription drugs throughout the country and identify counterfeit, stolen or contaminated medicine before it reached the hands of consumers.

SAP’s smart app is a major step in achieving the vision of the DSCSA and is vital to protecting communities and patient safety. When counterfeit drugs are released into the supply chain, vulnerable patients and marginalized populations with limited access to safe, authentic and affordable medicines bear the brunt of the impact.

“Patient safety is our top priority at our family-owned company, and unverified pharmaceuticals, especially amid a global pandemic, pose a significant threat to the safety and security of both patients and healthcare providers,” said Aaron Graham, Executive Director, Brand Safety & Security, Boehringer Ingelheim. “SAP’s blockchain-based solution allows our team to safeguard against illicit and unsafe medicines reaching the hands of those who need medicine the most.”

This technology builds on SAP’s previous efforts to eliminate counterfeit products with SAP Information Collaboration Hub for Life Sciences, a blockchain-technology tool that allows users to authenticate pharmaceutical packaging as it moves between manufacturers, U.S. wholesalers and U.S. hospitals and pharmacies.

To learn more, watch a webinar.

Visit the SAP News Center. Follow SAP on Twitter at @SAPNews.

Media Contact:
Stacy Ries, +1 (484) 619-0411, stacy.ries@sap.com, ET
SAP Press Room; press@sap.com

Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP’s future financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission (“SEC”), including SAP’s most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
© 2021 SAP SE. All rights reserved.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.